1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
4 |
| Hold |
1 |
| Sell |
1 |
News Go to news feed
Cosciens Biopharma reports improved quarterly result despite a loss
Cosciens Biopharma reported a loss of CAD 0.26 per share for the latest quarter, after a loss of CAD 3.53 in the year-ago quarter. Revenue rose to CAD 4.4 million from CAD 3.8 million a year earlier. The company thus shows a marked improvement in results with moderate revenue growth. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 2.68M | 13.59% |
| Gross profit | 1.48M | 77.18% |
| Net profit | -172.43K | 92.57% |
| EBITDA | 647.88K | 136.50% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.81M |
Number of shares | 1.06M |
52-week high/low | €24.57 - €4.34 |
| Dividends | No |
Beta | 1.89 |
P/E ratio | -0.40 |
PEG ratio | -0.01 |
P/B ratio | 0.37 |
P/S ratio | 0.68 |
Company profile
| Name | COSCIENS Biopharma |
| CEO | Peter Harry Puccetti |
| Employees | 28 |
Discover assets
Shareholders of COSCIENS Biopharma also invest in the following assets
